CDK4/6 Inhibitors in Breast Cancer: An Oncology Nurse’s Toolkit to Enhance Tolerability and Preserve Benefit

Achieve a greater understanding of the toxicities associated with CDK4/6 inhibitor therapy in HR+/HER2- breast cancer to effectively monitor and manage adverse events as well as strategies that can be implemented to increase adherence through an on-demand webcast, downloadable slides and accompanying resource, and expert-written ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation